News

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Q1 2025 Earnings Call Transcript May 1, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $1.13, ...
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here’s what to look ...
Compared to the aggregate P/E ratio of the 52.0 in the Biotechnology industry, Biomarin Pharmaceutical Inc. has a lower P/E ...
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, ...
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported first-quarter net income of $185.7 million. The San Rafael, California-based ...
Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...
Management addressed potential pharmaceutical tariffs, highlighting BioMarin's global business model as a mitigating factor. Analysts voiced concerns about competition for VOXZOGO and long-term ...
Enzyme Therapies revenues grew 8% in the first quarter Y/Y, driven by strong continued demand for PALYNZIQ. Strong PALYNZIQ performance as well as solid growth from BioMarin's other enzyme treatments ...
Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President - Finance; Biomarin Pharmaceutical Inc ...
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported first-quarter net income of $185.7 million. The San Rafael, California-based company said ...
On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Brian Mueller, Executive Vice President, Chief Financial Officer; Cristin Hubbard, Executive Vice ...